Literature DB >> 27053553

Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine.

Anne B Kristensen1,2, William N Lay1, Fernanda Ana-Sosa-Batiz1, Hillary A Vanderven1, Vijaya Madhavi1, Karen L Laurie3, Louise Carolan3, Bruce D Wines4,5,6, Mark Hogarth4,5,6, Adam K Wheatley1, Stephen J Kent7,8,9.   

Abstract

UNLABELLED: This study seeks to assess the ability of seasonal trivalent inactivated influenza vaccine (TIV) to induce nonneutralizing antibodies (Abs) with Fc-mediated functions in HIV-uninfected and HIV-infected subjects. Functional influenza-specific Ab responses were studied in 30 HIV-negative and 27 HIV-positive subjects immunized against seasonal influenza. All 57 subjects received the 2015 TIV. Fc-mediated antihemagglutinin (anti-HA) Ab activity was measured in plasma before and 4 weeks after vaccination using Fc-receptor-binding assays, NK cell activation assays, and phagocytosis assays. At baseline, the HIV-positive group had detectable but reduced functional Ab responses to both vaccine and nonvaccine influenza antigens. TIV enhanced Fc-mediated Ab responses in both HIV-positive and HIV-negative groups. A larger rise was generally observed in the HIV-positive group, such that there was no difference in functional Ab responses between the two groups after vaccination. The 2015 TIV enhanced functional influenza-specific Ab responses in both HIV-negative and HIV-positive subjects to a range of influenza HA proteins. The increase in functional Ab responses in the HIV-positive group supports recommendations to immunize this at-risk group. IMPORTANCE: Infection with HIV is associated with increasing disease severity following influenza infections, and annual influenza vaccinations are recommended for this target group. However, HIV-infected individuals respond relatively poorly to vaccination compared to healthy individuals, particularly if immunodeficient. There is therefore a need to increase our understanding of immunity to influenza in the context of underlying HIV infection. While antibodies can mediate direct virus neutralization, interactions with cellular Fc receptors may be important for anti-influenza immunity in vivo by facilitating antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent phagocytosis (ADP). The ability of seasonal influenza vaccines to induce antibody responses with potent Fc-mediated antiviral activity is currently unclear. Probing the ADCC and ADP responses to influenza vaccination has provided important new information in the quest to improve immunity to influenza.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27053553      PMCID: PMC4886795          DOI: 10.1128/JVI.00285-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.

Authors:  Gregor F Lichtfuss; Wan-Jung Cheng; Yagmur Farsakoglu; Geza Paukovics; Reena Rajasuriar; Pushparaj Velayudham; Marit Kramski; Anna C Hearps; Paul U Cameron; Sharon R Lewin; Suzanne M Crowe; Anthony Jaworowski
Journal:  J Immunol       Date:  2012-06-27       Impact factor: 5.422

2.  Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo.

Authors:  David J DiLillo; Gene S Tan; Peter Palese; Jeffrey V Ravetch
Journal:  Nat Med       Date:  2014-01-12       Impact factor: 53.440

3.  Compromised B cell responses to influenza vaccination in HIV-infected individuals.

Authors:  Angela Malaspina; Susan Moir; Susan M Orsega; Joshua Vasquez; Natalie J Miller; Eileen T Donoghue; Shyamasundaran Kottilil; Misrak Gezmu; Dean Follmann; Galina M Vodeiko; Roland A Levandowski; JoAnn M Mican; Anthony S Fauci
Journal:  J Infect Dis       Date:  2005-03-24       Impact factor: 5.226

4.  Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study.

Authors:  Edwin Leeansyah; Jingling Zhou; Geza Paukovics; Sharon R Lewin; Suzanne M Crowe; Anthony Jaworowski
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

5.  Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

Authors:  Sinthujan Jegaskanda; Emma R Job; Marit Kramski; Karen Laurie; Gamze Isitman; Robert de Rose; Wendy R Winnall; Ivan Stratov; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Immunol       Date:  2013-01-14       Impact factor: 5.422

6.  Antibody-dependent cell-mediated cytotoxicity against influenza virus-infected cells.

Authors:  G Hashimoto; P F Wright; D T Karzon
Journal:  J Infect Dis       Date:  1983-11       Impact factor: 5.226

7.  Standard trivalent influenza virus protein vaccination does not prime antibody-dependent cellular cytotoxicity in macaques.

Authors:  Sinthujan Jegaskanda; Thakshila H Amarasena; Karen L Laurie; Hyon-Xhi Tan; Jeff Butler; Matthew S Parsons; Sheilajen Alcantara; Janka Petravic; Miles P Davenport; Aeron C Hurt; Patrick C Reading; Stephen J Kent
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

8.  Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1.

Authors:  Sinthujan Jegaskanda; Karen L Laurie; Thakshila H Amarasena; Wendy R Winnall; Marit Kramski; Robert De Rose; Ian G Barr; Andrew G Brooks; Patrick C Reading; Stephen J Kent
Journal:  J Infect Dis       Date:  2013-06-28       Impact factor: 5.226

9.  Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy.

Authors:  Anna M Iorio; Daniela Francisci; Barbara Camilloni; Giuliano Stagni; Matteo De Martino; Daniela Toneatto; Roberto Bugarini; Mariella Neri; Audino Podda
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

10.  Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.

Authors:  Amy W Chung; Musie Ghebremichael; Hannah Robinson; Eric Brown; Ickwon Choi; Sophie Lane; Anne-Sophie Dugast; Matthew K Schoen; Morgane Rolland; Todd J Suscovich; Alison E Mahan; Larry Liao; Hendrik Streeck; Charla Andrews; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Mark S de Souza; Jaranit Kaewkungwal; Punnee Pitisuttithum; Donald Francis; Nelson L Michael; Jerome H Kim; Chris Bailey-Kellogg; Margaret E Ackerman; Galit Alter
Journal:  Sci Transl Med       Date:  2014-03-19       Impact factor: 17.956

View more
  26 in total

1.  Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity.

Authors:  Amy W Chung; Jenniffer M Mabuka; Bongiwe Ndlovu; Anna Licht; Hannah Robinson; Yathisha Ramlakhan; Musie Ghebremichael; Tarylee Reddy; Philip J R Goulder; Bruce D Walker; Thumbi Ndung'u; Galit Alter
Journal:  AIDS       Date:  2018-06-19       Impact factor: 4.177

2.  HIV-1 Env- and Vpu-Specific Antibody-Dependent Cellular Cytotoxicity Responses Associated with Elite Control of HIV.

Authors:  Vijaya Madhavi; Bruce D Wines; Janaki Amin; Sean Emery; Ester Lopez; Anthony Kelleher; Rob J Center; P Mark Hogarth; Amy W Chung; Stephen J Kent; Ivan Stratov
Journal:  J Virol       Date:  2017-08-24       Impact factor: 5.103

3.  Self-assembling influenza nanoparticle vaccines drive extended germinal center activity and memory B cell maturation.

Authors:  Hannah G Kelly; Hyon-Xhi Tan; Jennifer A Juno; Robyn Esterbauer; Yi Ju; Wenbo Jiang; Verena C Wimmer; Brigette C Duckworth; Joanna R Groom; Frank Caruso; Masaru Kanekiyo; Stephen J Kent; Adam K Wheatley
Journal:  JCI Insight       Date:  2020-05-21

Review 4.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

5.  Brief Report: Decreased JC Virus-Specific Antibody-Dependent Cellular Cytotoxicity in HIV-Seropositive PML Survivors.

Authors:  Chen S Tan; Joshua Ghofrani; Emma Geiger; Igor J Koralnik; Stephanie Jost
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

6.  A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies.

Authors:  Mark J Bailey; Felix Broecker; Paul E Leon; Gene S Tan
Journal:  J Vis Exp       Date:  2018-02-23       Impact factor: 1.355

7.  Fc functional antibodies in humans with severe H7N9 and seasonal influenza.

Authors:  Hillary A Vanderven; Lu Liu; Fernanda Ana-Sosa-Batiz; Thi Ho Nguyen; Yanmin Wan; Bruce Wines; P Mark Hogarth; Danielle Tilmanis; Arnold Reynaldi; Matthew S Parsons; Aeron C Hurt; Miles P Davenport; Tom Kotsimbos; Allen C Cheng; Katherine Kedzierska; Xiaoyan Zhang; Jianqing Xu; Stephen J Kent
Journal:  JCI Insight       Date:  2017-07-06

8.  Anti-Influenza Hyperimmune Immunoglobulin Enhances Fc-Functional Antibody Immunity During Human Influenza Infection.

Authors:  Hillary A Vanderven; Kathleen Wragg; Fernanda Ana-Sosa-Batiz; Anne B Kristensen; Sinthujan Jegaskanda; Adam K Wheatley; Deborah Wentworth; Bruce D Wines; P Mark Hogarth; Steve Rockman; Stephen J Kent
Journal:  J Infect Dis       Date:  2018-09-22       Impact factor: 5.226

9.  Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.

Authors:  Yinghua Li; Zhengfang Lin; Min Guo; Yu Xia; Mingqi Zhao; Changbing Wang; Tiantian Xu; Tianfeng Chen; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2017-08-09

10.  HIV-dependent depletion of influenza-specific memory B cells impacts B cell responsiveness to seasonal influenza immunisation.

Authors:  Adam K Wheatley; Anne B Kristensen; William N Lay; Stephen J Kent
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.